Patent ID: 7199143
Filing Date: 2007-04-03
Classification: A61P,C07D

Abstract:
1. A compound of the formula (I), or a pharmaceutically-acceptable salt, or an in-vivo-hydrolysable ester thereof, wherein —N-HET is selected from the structures (Id) or (Ie) below: wherein; R1 is selected from a substituent from the group (R1a) wherein R1 is halogen, hydroxy, (1–4C)alkoxy, (2–4C)alkenyloxy, (2–4C)alkenyl, (2–4C)alkynyl (optionally substituted on the terminal carbon by CH or R1 is selected from the group (R1b) wherein R1 is a (1–4C)alkyl group which is substituted by one substituent selected from hydroxy, halo, (1–4C)alkoxy, (2–4C)alkenyloxy, (1–4C)alkyl-S(O)q- (wherein q is 0, 1 or 2), AR1-S(O)q- (wherein q is 0, 1 or 2 and AR1 is defined hereinbelow), AR2-S(O)q- (wherein q is 0, 1 or 2), AR2a-S(O)q- (wherein q is 0, 1 or 2), benzyl-S(O)q- (wherein q is 0, 1 or 2), (3–6C)cycloalkyl, (3–6C)cycloalkenyl, (1–4C)alkyl-OCO—NH—; or R1 is selected from a group of formula (R1c1): (R1c1) a fully saturated 4-membered monocyclic ring containing 1 or 2 heteroatoms independently selected from O and S (optionally oxidised), and linked via a ring nitrogen or carbon atom; or or R1 is selected from the group (R1d) formyl, (1–4C)alkylcarbonyl, (1–4C)alkoxycarbonyl; and wherein at each occurrence of an R1 substituent containing an alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkenyl moiety in (R1a), (R1b) or (R1c1) each such moiety is optionally further substituted on an available carbon atom with one, two, three or more substituents independently selected from F, Cl Br, and OH; Q is Q1; wherein R 2 and R 3 independently selected from H, F, Cl, CF 3 , OMe, SMe, Me and Et; wherein B, is O or S; wherein T is (TC4): wherein in (TC4): n1 is 1 or 2; o1 is 1 or 2 and n1+o1=2 or 3; >A 3 -B 3 - is >C═C(Rr)- and G is —S—, —SO—, —SO 2 —; Rp is hydrogen (1–4C)alkyl (other than when such substitution is defined by >A 3 -B 3 ), hydroxy, (1–4C)alkoxy or (1–4C)alkanoyloxy; Rr is (independently where appropriate) hydrogen or (1–4C)alkyl; and, other than the ring substitution defined by G, >A wherein AR1 is an optionally substituted phenyl or optionally substituted naphthyl; AR2 is an optionally substituted 5- or 6-membered, fully unsaturated (i.e with the maximum degree of unsaturation) monocyclic heteroaryl ring containing up to four heteroatoms independently selected from O, N and S (but not containing any O—O, O—S or S—S bonds), and linked via a ring carbon atom, or a ring nitrogen atom if the ring is not thereby quaternised; AR2a is a partially hydrogenated version of AR2 (i.e. AR2 systems retaining some, but not the full, degree of unsaturation), linked via a ring carbon atom or linked via a ring nitrogen atom if the ring is not thereby quaternised.